Avivagen Announces its Attendance at BIOSPAIN 2018
September 24 2018 - 6:30AM
Avivagen Inc. (TSXV:VIV) (“Avivagen), is pleased to announce that
it will be attending BIOSPAIN 2018, in Seville, Spain, from
September 25th-27th, 2018. Avivagen was invited to attend by the
Department of Foreign Affairs, Trade & Development, Canada
(DFATD) and is representing Canada with Mr. Kym Anthony, Avivagen’s
Chairman & Interim CEO, as its Expert Speaker at this year’s
conference. Avivagen will also be conducting business development
activities at the event.
BIOSPAIN (https://biospain2018.org) is the largest biotech event
organized by a national bioindustry association in Europe and one
of the largest in the world by the number of one-on-one meetings
(+3,000) and companies participating (+800), with 34% of delegates
coming from outside of Spaini. The conference is organized by
ASEBIO, the Spanish Bioindustry Association and each edition is
co-organized by a local institution from the host
city/region.
About AvivagenAvivagen is a life sciences
Corporation focused on developing and commercializing products for
livestock, companion animal and human applications that, by safely
supporting immune function, promote general health and
performance. It is a public Corporation traded on the TSX
Venture Exchange under the symbol VIV and is headquartered in
Ottawa, Canada, based in partnership facilities of the National
Research Council of Canada and Charlottetown, Prince Edward Island.
For more information, visit www.avivagen.com. The contents of the
website are expressly not incorporated by reference in this press
release.
About OxC-beta™ Technology and OxC-beta™
LivestockAvivagen’s OxC-beta™ technology is derived from
Avivagen discoveries about carotenoids, compounds that give certain
fruits and vegetables their bright colours, and is a non-antibiotic
means of maintaining optimal health and growth. OxC-beta™ Livestock
is a proprietary product shown to be effective and economic in
replacing the antibiotics commonly added to livestock feeds.
OxC-beta™ Livestock is currently registered and available for sale
in the Philippines, Taiwan, Thailand and New Zealand.
Avivagen’s OxC-beta™ Livestock product is safe, effective and
could fulfill the global mandate to remove all in-feed antibiotics
as growth promoters. Numerous international livestock trials with
poultry and swine using OxC-beta™ Livestock have proven that the
product performs as well as, and, sometimes, in some aspects,
better than in-feed antibiotics.
Forward Looking StatementsThis news release
includes certain forward-looking statements that are based upon the
current expectations of management. Forward-looking statements
involve risks and uncertainties associated with the business of
Avivagen Inc. and the environment in which the business operates.
Any statements contained herein that are not statements of
historical facts may be deemed to be forward-looking, including
those identified by the expressions “aim”, “anticipate”, “appear”,
“believe”, “consider”, “could”, “estimate”, “expect”, “if”,
“intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”,
“potentially”, “pursue”, “seem”, “should”, “whether”, “will”,
“would” and similar expressions. Statements set out in this news
release relating to the expectation that OxC-beta™ Livestock could
fulfill the global mandate to remove all in-feed antibiotics as
growth promoters are forward-looking statements. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results or events to differ
materially from current expectations. For instance, Avivagen’s
products may not gain market acceptance or regulatory approval in
new jurisdictions or for new applications and may not be widely
accepted as a replacement for antibiotics in livestock
feeds. Except as required by law, Avivagen assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those reflected in
the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For more information:Avivagen Inc.Drew
BasekDirector of Investor Relations100 Sussex Drive, Ottawa,
Ontario, Canada K1A 0R6 Phone: 416-540-0733E-mail:
d.basek@avivagen.com
Kym AnthonyChairman & Interim CEO100 Sussex Drive, Ottawa,
Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164Website:
www.avivagen.com
Copyright © 2018 Avivagen Inc. OxC-beta™ is a trademark of
Avivagen Inc.
i Biospain 2018 Website www.biospain2018.org
Avivagen (TSXV:VIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avivagen (TSXV:VIV)
Historical Stock Chart
From Apr 2023 to Apr 2024